Driehaus Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12.9M | Sell |
42,746
-16,876
| -28% | -$5.09M | 0.07% | 263 |
|
|
2026
Q1 | $19.7M | Sell |
59,622
-10,156
| -15% | -$3.46M | 0.15% | 205 |
|
|
2025
Q4 | $27.7M | Buy |
69,778
+8,399
| +14% | +$3.72M | 0.19% | 163 |
|
|
2025
Q3 | $28M | Sell |
61,379
-18,335
| -23% | -$7.47M | 0.2% | 163 |
|
|
2025
Q2 | $26M | Buy |
79,714
+22,586
| +40% | +$6.25M | 0.21% | 150 |
|
|
2025
Q1 | $15.4M | Buy |
57,128
+23,648
| +71% | +$6.08M | 0.15% | 192 |
|
|
2024
Q4 | $7.88M | Buy |
33,480
+1,130
| +3% | +$297K | 0.07% | 274 |
|
|
2024
Q3 | $8.9M | Sell |
32,350
-139
| -0.4% | -$36.2K | 0.08% | 241 |
|
|
2024
Q2 | $7.89M | Buy |
+32,489
| New | +$5.13M | 0.08% | 234 |
|
|
2024
Q1 | – | Sell |
-38,988
| Closed | -$7.46M | – | 384 |
|
|
2023
Q4 | $7.46M | Sell |
38,988
-41
| -0.1% | -$6.98K | 0.09% | 247 |
|
|
2023
Q3 | $6.91M | Sell |
39,029
-9
| -0% | -$1.72K | 0.09% | 256 |
|
|
2023
Q2 | $7.41M | Buy |
39,038
+2,778
| +8% | +$551K | 0.09% | 250 |
|
|
2023
Q1 | $7.26M | Sell |
36,260
-32,991
| -48% | -$6.93M | 0.1% | 260 |
|
|
2022
Q4 | $16.5M | Buy |
69,251
+1,169
| +2% | +$249K | 0.25% | 140 |
|
|
2022
Q3 | $13.6M | Buy |
68,082
+11,812
| +21% | +$2.25M | 0.21% | 150 |
|
|
2022
Q2 | $8.21M | Buy |
56,270
+1,821
| +3% | +$258K | 0.13% | 219 |
|
|
2022
Q1 | $8.89M | Sell |
54,449
-8,562
| -14% | -$1.3M | 0.11% | 247 |
|
|
2021
Q4 | $10.7M | Buy |
63,011
+18,509
| +42% | +$3.44M | 0.11% | 233 |
|
|
2021
Q3 | $8.4M | Buy |
44,502
+41,723
| +1,501% | +$7.83M | 0.1% | 256 |
|
|
2021
Q2 | $471K | Sell |
2,779
-29
| -1% | -$4.25K | 0.01% | 373 |
|
|
2021
Q1 | $396K | Sell |
2,808
-813
| -22% | -$122K | 0.01% | 395 |
|
|
2020
Q4 | $471K | Buy |
3,621
+31
| +0.9% | +$4.14K | 0.01% | 369 |
|
|
2020
Q3 | $523K | Buy |
3,590
+438
| +14% | +$62.2K | 0.01% | 330 |
|
|
2020
Q2 | $467K | Buy |
3,152
+172
| +6% | +$23.2K | 0.01% | 321 |
|
|
2020
Q1 | $324K | Buy |
2,980
+699
| +31% | +$80.7K | 0.01% | 335 |
|
|
2019
Q4 | $263K | Buy |
+2,281
| New | +$227K | 0.01% | 461 |
|
|
2018
Q4 | – | Sell |
-4,843
| Closed | -$424K | – | 402 |
|
|
2018
Q3 | $424K | Buy |
4,843
+95
| +2% | +$9.56K | 0.01% | 412 |
|
|
2018
Q2 | $468K | Sell |
4,748
-600
| -11% | -$59.5K | 0.02% | 399 |
|
|
2018
Q1 | $637K | Sell |
5,348
-25
| -0.5% | -$3.22K | 0.02% | 385 |
|
|
2017
Q4 | $683K | Sell |
5,373
-6,436
| -55% | -$809K | 0.03% | 369 |
|
|
2017
Q3 | $1.39M | Buy |
11,809
+1,926
| +19% | +$164K | 0.05% | 284 |
|
|
2017
Q2 | $788K | Buy |
+9,883
| New | +$632K | 0.03% | 370 |
|
|
2016
Q4 | – | Sell |
-8,102
| Closed | -$549K | – | 523 |
|
|
2016
Q3 | $549K | Buy |
8,102
+111
| +1% | +$7.83K | 0.02% | 423 |
|
|
2016
Q2 | $443K | Buy |
+7,991
| New | +$503K | 0.02% | 448 |
|
|
2016
Q1 | – | Sell |
-8,993
| Closed | -$847K | – | 541 |
|
|
2015
Q4 | $847K | Buy |
8,993
+5,928
| +193% | +$550K | 0.03% | 395 |
|
|
2015
Q3 | $246K | Sell |
3,065
-24,083
| -89% | -$2.68M | 0.01% | 492 |
|
|
2015
Q2 | $3.25M | Sell |
27,148
-1,978
| -7% | -$236K | 0.11% | 231 |
|
|
2015
Q1 | $3.04M | Sell |
29,126
-22,640
| -44% | -$2.29M | 0.11% | 241 |
|
|
2014
Q4 | $5.02M | Sell |
51,766
-40,554
| -44% | -$3.76M | 0.2% | 144 |
|
|
2014
Q3 | $7.21M | Sell |
92,320
-46,806
| -34% | -$3.02M | 0.27% | 92 |
|
|
2014
Q2 | $8.79M | Sell |
139,126
-70,215
| -34% | -$4.17M | 0.29% | 84 |
|
|
2014
Q1 | $14.1M | Buy |
209,341
+82,915
| +66% | +$6.42M | 0.44% | 48 |
|
|
2013
Q4 | $8.13M | Sell |
126,426
-130,834
| -51% | -$7.8M | 0.29% | 96 |
|
|
2013
Q3 | $16.5M | Sell |
257,260
-70,871
| -22% | -$3.53M | 0.64% | 33 |
|
|
2013
Q2 | $10.2M | Buy |
+328,131
| New | +$8.73M | 0.44% | 59 |
|
Other funds holding ALNY
Driehaus Capital Management's ALNY Position: Q2 2026 in Review
Driehaus Capital Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 28% in Q2 2026, selling an estimated $5.09M and leaving 42,746 shares worth $12.9M. The position accounts for 0.07% of the portfolio, ranked #263.
Driehaus Capital Management first reported a position in ALNY in Q2 2013 and has held it in 45 quarters since. The position peaked at $28M in Q3 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Driehaus Capital Management held 42,746 shares of Alnylam Pharmaceuticals worth $12.9M as of Q2 2026.
- Driehaus Capital Management sold 16,876 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $5.09M.
- Alnylam Pharmaceuticals made up 0.07% of Driehaus Capital Management's portfolio in Q2 2026, its #263 holding.
- Driehaus Capital Management first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
- Driehaus Capital Management's Alnylam Pharmaceuticals position peaked at $28M in Q3 2025.
- 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.